Wednesday, October 14, 2026

Corporate Accountability

2 articles

AI Ethics Researchers Document Big Tech Market Pressure on Global South Startups

AI ethics researchers Timnit Gebru and Abeba Birhane are challenging corporate 'AI for Good' narratives as PR deflection, documenting cases where Big Tech model announcements triggered investor pressure on small language AI startups to shut down. Meta's 200-language translation model announcement led investors to demand closure of African language NLP startups, while OpenAI representatives allegedly offered minimal compensation for data while threatening obsolescence.

ViaNews Editorial Team (Finance)•Feb 28, 2026

Big Tech AI Ethics Under Fire as Researchers Expose 'Data Theft' and Labor Exploitation

AI researchers Timnit Gebru and Abeba Birhane are dismantling corporate 'AI for Good' narratives, exposing what they call systemic data theft, environmental damage, and labor exploitation in AI development. The critique threatens Big Tech's regulatory standing as African governments adopt AI rhetoric with minimal scrutiny of impacts on civil liberties.

ViaNews Editorial Team (Finance)•Feb 21, 2026

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe

October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,375 source documents archived

Query this data → isubstrate.com